PharmTech Drug Digest 11.20
|Articles|August 29, 2013

Cubist Pharmaceuticals Recalls Vials With Glass Particulate

Cubist issued a voluntary recall of four lots of vials due to the presence of particulate matter.

Cubist Pharmaceuticals announced that it is voluntarily recalling four lots of Cubicin (daptomycin for injection) to the user level due to the presence of particulate matter found in a number of vials from these lots, Cubist announced in a press release.

The lots of 500-mg Cubicin in 10-mL, single-use vials were shipped between May 2011 and March 2013. An internal investigation has preliminarily identified the root cause as a manufacturing issue with a supplier, and Cubist has suspended all manufacturing with the supplier until corrective and preventative measures have been taken.

Cubist is notifying customers by letter and phone and notes that existing inventory should be checked. Cubist is arranging for return of recalled product. Glass particulate in an intravenous drug poses a potential safety risk to patients, but no adverse events related to the recall have been reported to date.


Related to this article

white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Green Chemistry Supply and Demand in Sustainable Pharma
Celtic Renewables won the CPHI Award for Sustainable Pharma Excellence for its green chemicals used in pharmaceutical manufacturing. Bettina Brierley, chief commercial officer, talks about the adoption, capacity, and pricing of biosolvents.